Source : Perth Now news
Puberty blockers should remain a treatment option for trans and gender-diverse people but more scrutiny of their use is needed, new draft guidelines show.
The National Health and Medical Research Council published interim advice on Monday for treating children whose gender is different from their sex recorded at birth – known as gender incongruence.
Puberty blockers were one possible part of care, the council said.
They said the medication should come with an assessment of a patient’s goals, health, whether they met the criteria for gender incongruence, their social environment and stage of puberty.
That should be paired with input from the likes of GPs, psychiatrists and social workers, although access to puberty blockers should not depend on these services’ availability, the advice said.
They added it was not necessary to wait for a patient to be distressed – a state known as gender dysphoria – or to start transitioning socially before prescribing the treatment.
“We’re talking about a relatively small group of young people, but it is a growing group,” Health Minister Mark Butler told reporters in Canberra.
“It was especially important to give those young Australians … the greatest possible confidence that clinicians treating and caring for these young Australians have access to and are using the best possible clinical guidelines.”
The draft advice conflicts with policy in Queensland, where puberty blockers are restricted in the public health system, and in the Northern Territory, where they’re banned.
It was up to those jurisdictions as to whether they followed the council’s new guidance, Mr Butler said.
Advocacy group Equality Australia welcomed the provisional codes.
“Trans young people … are being denied access to health care that Australia’s peak medical research body recognises,” chief executive Anna Brown said.
“This advice reinforces that the care trans young people are receiving in Australia today is grounded in evidence.”
The new guidance was informed by 15 studies reporting data from 12,756 people.
They found puberty blockers had little to no effect on gender dysphoria and body image among patients, although those verdicts were very uncertain.
The medication may improve social functioning and reduce patients’ desire to take their own lives, the surveys found, but they also harboured doubt about those conclusions.
The council’s recommendations differed starkly from the UK’s much-debated 2024 review into gender-affirming care, which found little evidence for the need for puberty suppression and led to the treatment being banned.
Mr Butler said Australia was different to Britain, where many private clinics had sprung up prescribing hormone suppressants inadvisably.
“(It) often involved simply the completion of an online questionnaire and a single zoom call with a prescribing practitioner who was sometimes not even in the UK,” he said.
The research council’s advice is open for consultation until January, with full guidelines due in 2028.
Lifeline 13 11 14
Kids Helpline 1800 55 1800 (for people aged 5 to 25)



